"Unrealistic" to share North American antiviral supply

Murray, Sally
September 2005
CMAJ: Canadian Medical Association Journal;9/27/2005, Vol. 173 Issue 7, p743
Academic Journal
Reports on the decision of the U.S. and Canada not to share influenza antiviral treatment supply to developing countries, as of September 2005. Reason behind the decision; Details of the massive international effort to share influenza treatment; Various comments on the matter.


Related Articles

  • Investigational antiviral reduces duration, eases severity of viral respiratory infections.  // Formulary;Feb2002, Vol. 37 Issue 2, p64 

    Investigates an experimental antiviral medication for the treatment of viral respiratory infections in the United States. Manifestations of picornaviruses; Details on the overall time to alleviation of viral respiratory infections; Implications of the study.

  • Human Immunodeficiency Virus Type 1--Related Pulmonary Mycobacterium xenopi Infection: A Need to Treat? Kerbiriou, L.; Ustianowski, A.; Johnson, M. A.; Gillespie, S. H.; Miller, R. F.; Lipman, M. C. I. // Clinical Infectious Diseases;11/1/2003, Vol. 37 Issue 9, p1250 

    We report treatment decisions and outcomes for 20 patients who were infected with human immunodeficiency virus type 1 (HIV-1) and were receiving highly active antiretroviral therapy (HAART) who had respiratory symptoms and from whom Mycobacterium xenopi was isolated. All patients also had...

  • Prevalence of Influenza A(H1N1)pdm09 Virus Resistant to Oseltamivir in Shiraz, Iran, During 2012-2013. Khodadad, Nastaran; Moattari, Afagh; Shahr Abadi, Mahmoud Shamsi; Kadivar, Mohammad Rahim; Sarvari, Jamal; Tavakoli, Forough; Pirbonyeh, Neda; Emami, Amir // Jundishapur Journal of Microbiology;Aug2015, Vol. 8 Issue 8, p1 

    Background: Oseltamivir has been used as a drug of choice for the prophylaxis and treatment of human influenza A(H1N1)pdm09 infection across the world. However, the most frequently identified oseltamivir resistant virus, influenza A(H1N1)pdm09, exhibit the H275Y substitution in NA gene....

  • Clinical Activity of Pleconaril in an Experimentally Induced Coxsackievirus A21 Respiratory... Schiff, Gilbert M.; Sherwood, James R. // Journal of Infectious Diseases;1/1/2000, Vol. 181 Issue 1, p20 

    Assesses the efficacy and safety of pleconaril, an antiviral drug with spectrum activity against picornaviruses, in the treatment of viral respiratory infection. Signs and symptoms of the illness; Interruption of viral protein action; Adverse events associated with the drug.

  • Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries. Bourinbaiar, Aldar S.; Jirathitikal, Vichai // Current Pharmaceutical Design;Jul2003, Vol. 9 Issue 18, p1419 

    A considerable progress has been made in recent years in the field of drug development against HIV. However, the current cost of AIDS drugs is the main obstacle that prevents their use in developing countries, where 95% of HIVinfected patients reside. The average yearly price of AIDS therapy and...

  • Movement made on AIDS drug prices. Highleyman, Liz // Bay Area Reporter;4/12/2001, Vol. 31 Issue 15, p18 

    Reports on a movement made on AIDS drug prices for developing countries. Limitation of drug patent protections; Concerns related to collaborative price-fixing; Funding for anti-HIV drugs.

  • Narrowing the gap: access to HIV treatments in developing countries. A pharmaceutical... Cochrane, James; Bayley, Anne // Journal of Medical Ethics;Feb2000, Vol. 26 Issue 1, p47 

    The advent of new antiretroviral medicines means that the effects of HIV can now be curbed, but only one in twenty infected people have so far benefited. For those living in developing countries, the new treatments are practically unattainable. Governments, UNAIDS and pharmaceutical companies...

  • Controversy over Gilead licensing agreement.  // HIV Australia;2011, Vol. 9 Issue 2, p5 

    The article reports that the International Treatment Preparedness Coalition (ITPC) has expressed concerns related to license agreement between the Medicines Patent Pool and the company Gilead as it thinks that this will exclude many developing countries from accessing HIV antiretroviral therapy.

  • In Silico Study of Rotavirus VP7 Surface Accessible Conserved Regions for Antiviral Drug/Vaccine Design. Ghosh, Ambarnil; Chattopadhyay, Shiladitya; Chawla-Sarkar, Mamta; Nandy, Papiya; Nandy, Ashesh // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    Background: Rotaviral diarrhoea kills about half a million children annually in developing countries and accounts for one third of diarrhea related hospitalizations. Drugs and vaccines against the rotavirus are handicapped, as in all viral diseases, by the rapid mutational changes that take...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics